(Q35621745)

9 August 2017

1 reference

title

Treatment of chronic hepatitis B in children. (English)

1 reference

9 August 2017

1 reference

1 reference

Flavia Bortolotti

1

1 reference

9 August 2017

publication date

1 January 2003

1 reference

9 August 2017

published in

Journal of Hepatology

1 reference

9 August 2017

volume

39 Suppl 1

1 reference

9 August 2017

page(s)

S200-5

1 reference

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Natural history of hepatitis B virus infection in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Natural history of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Long-term persistence of hepatitis B virus DNA in the serum of children with chronic hepatitis B after hepatitis B e antigen to antibody seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Liver cirrhosis associated with chronic hepatitis B virus infection in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Precore mutant hepatitis B virus and outcome of chronic infection and hepatitis in hepatitis B e antigen-positive children.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Primary hepatocellular carcinoma and hepatitis B infection during childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Is interferon therapy in pediatric chronic hepatitis B infection warranted?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Why treat chronic hepatitis B in childhood with interferon alpha?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Long term effect of alpha interferon in children with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Factors predictive of response to interferon therapy in children with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Statistical models for predicting response to interferon-alpha and spontaneous seroconversion in children with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Dual‐centre, double‐blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Pilot interferon-beta trial in children with chronic hepatitis B who had previously not responded to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Levamisole and interferon in children with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Safety and efficacy of interferon retreatment in children with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Nutritional status and growth in children with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Impact of chronic hepatitis B and interferon-alpha therapy on growth of children

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Cost-benefit analysis of interferon therapy in children with chronic active hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Clinical trial of lamivudine in children with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Lamivudine-interferon combination therapy for chronic hepatitis B: further support but no conclusive evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900328-3

7 January 2021

10.1016/S0168-8278(03)00328-3

Identifiers

DOI

1 reference

9 August 2017

1 reference